Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate

Kezar Life Sciences, Inc. (NASDAQ:KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

The MISSION Phase 2 clinical trial study is designed to demonstrate the responder rate of zetomipzomib in patients with active lupus nephritis (LN).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.